Brokers Offer Predictions for EPRX Q2 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Eupraxia Pharmaceuticals in a research report issued on Thursday, June 26th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.29) EPS.

Separately, Canaccord Genuity Group started coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a "speculative buy" rating for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of "Buy" and an average price target of $11.00.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX traded up $0.08 during mid-day trading on Monday, reaching $5.47. 8,647 shares of the company's stock were exchanged, compared to its average volume of 13,313. Eupraxia Pharmaceuticals has a one year low of $2.20 and a one year high of $6.20. The business's fifty day simple moving average is $4.12 and its two-hundred day simple moving average is $3.62. The firm has a market capitalization of $196.51 million, a PE ratio of -7.19 and a beta of 1.55.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EPRX. Millennium Management LLC bought a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth about $31,000. Raymond James Financial Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $37,000. Bank of Montreal Can increased its stake in Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after acquiring an additional 7,500 shares during the last quarter. Royal Bank of Canada raised its position in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after purchasing an additional 59,683 shares in the last quarter. Finally, Scotia Capital Inc. raised its position in Eupraxia Pharmaceuticals by 11.6% during the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock valued at $5,072,000 after purchasing an additional 160,960 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.